A randomized, controlled, double blind, double dummy clinical trial to evaluate the safety and efficacy of Loxoprofen Sodium Cataplasm Ointment (Loxonin®PAP100mg) against knee osteoarthritis

ead Chemical Co. Ltd (Japan)0 个研究点目标入组 160 人开始时间: 2012年12月13日最近更新: 2017年7月24日

适应症

试验速览

暂无简介。

•1. Age: > 18 years, < 80 years
•2. Sex: unrestricted
•3. Patients conforming to clinical diagnostic criteria
•4. Patients agree to participate this trial and sign informed content form after completely understanding the contents of the clinical trial

•1. Patients with digestive ulcers
•2. Patients with bronchial asthma
•3. Patients with serious cardiac diseases, hepatic diseases (ALT, AST are equal or bigger than 2.5 times of upper limit), renal diseases (creatinine is equal or bigger than 1.5 times of upper limit), hematologic disease, diabetes, mental diseases, and other serious complications
•4. Pregnant women, lactating women, patients with pregnancy potential, and patients who want to be pregnant during the clinical trial
•5. Patients with drug hypersensitivity (aspirin asthma, hypersensitive to loxoprofen sodium or other drugs)
•6. Patients with lesions, poor skin conditions on pasting site, or with cutaneous anaphylaxis (dermatitis due to external agent or patients with dermatitis)
•7. Patients combining other rheumatic diseases
•8. Patients who need steroid drugs or other non-steroid analgesics which may interfere the therapeutic method in this clinical trial
•9. Patients participating any clinical trials on investigational drug or marketing drug within 3 months before inclusion or during clinical trial
•10. Other patients judged to be inappropriate for this clinical trial by the investigator

发起方

ead Chemical Co. Ltd (Japan)